Clinical trial
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)
NCT07931573 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 10, 2026
- Completion date
- August 8, 2028
- Enrollment
- 1,200 (estimated)
- Sites
- 230
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes
Arms
As registered; 3 arms.
-
Zenagamtide
Participants will receive zenagamtide subcutaneously once weekly
-
Semaglutide
Participants will receive semaglutide subcutaneously once weekly
-
Placebo
Participants will receive placebo matched to semaglutide or zenagamtide subcutaneously once weekly
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in glycated haemoglobin (HbA1c) [non-inferiority]
Measured in percentage point
Lead sponsor's other trials
Novo Nordisk A/S, most recent start first.
+1,402 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,321 more trials See the condition page